21529, a novel adenylate cyclase
AssigneeMillennium Pharmaceuticals, Inc.
InventorsRosana Kapeller-Libermann, Miyoung Chun
Life of this patent
Estimating the term…
Abstract
Novel adenylate cyclase polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length adenylate cyclase proteins, the invention further provides isolated adenylate cyclase fusion proteins, antigenic peptides, and anti-adenylate cyclase antibodies. The invention also provides adenylate cyclase nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an adenylate cyclase gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
Claims19
A method for screening test compounds to identify a compound that binds to a polypeptide comprising an amino acid sequence selected from the group consisting of:
- a) the amino acid sequence of a sequence variant of the amino acid sequence set forth in SEQ ID NO:1, wherein said sequence variant has adenylate cyclase activity and is encoded by a nucleotide sequence having at least 75% sequence identity with the nucleotide sequence shown in SEQ ID NO:2;
- b) the amino acid sequence of a sequence variant of the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC as Patent Deposit No. PTA-1661, wherein said sequence variant has adenylate cyclase activity and is encoded by a nucleotide sequence having at least 75% sequence identity with the nucleotide sequence of the cDNA insert of the plasmid deposited with the ATCC as Patent Deposit No. PTA-1661;
- c) the amino acid sequence of a fragment of the amino acid sequence set forth in SEQ ID NO:1, wherein said fragment has adenylate cyclase activity and consists of at least 100 contiguous amino acids of the amino acid sequence set forth in SEQ ID NO:1;
- and
- d) the amino acid sequence of a fragment of the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC as Patent Deposit No. PTA-1661, wherein said fragment has adenylate cyclase activity and consists of at least 100 contiguous amino acids of the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC as Patent Deposit No. PTA-1661;
- said method comprising contacting the test compound with the polypeptide or a cell expressing the polypeptide under conditions suitable for binding of the compound to the polypeptide and determining whether a complex is formed between the test compound and the polypeptide.
A method for screening test compounds to identify a compound that modulates an activity of a polypeptide having an amino acid sequence selected from the group consisting of:
- a) the amino acid sequence of a sequence variant of the amino acid sequence set forth in SEQ ID NO:1, wherein said sequence variant has adenylate cyclase activity and is encoded by a nucleotide sequence having at least 75% sequence identity with the nucleotide sequence shown in SEQ ID NO:2;
- b) the amino acid sequence of a sequence variant of the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC as Patent Deposit No. PTA-1661, wherein said sequence variant has adenylate cyclase activity and is encoded by a nucleotide sequence having at least 75% sequence identity with the nucleotide sequence of the cDNA insert of the plasmid deposited with the ATCC as Patent Deposit No. PTA-1661;
- c) the amino acid sequence of a fragment of the amino acid sequence set forth in SEQ ID NO:1, wherein said fragment has adenylate cyclase activity and consists of at least 100 contiguous amino acids of the amino acid sequence set forth in SEQ ID NO:1;
- and
- d) the amino acid sequence of a fragment of the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC as Patent Deposit No. PTA-1661, wherein said fragment has adenylate cyclase activity and consists of at least 100 contiguous amino acids of the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC as Patent Deposit No. PTA-1661;
- said method comprising contacting the test compound with the polypeptide or a cell expressing the polypeptide under conditions suitable for detecting an activity of the polypeptide and assaying the ability of the test compound to modulate the activity of the polypeptide.
A method screening test compounds to identify a compound that binds to a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:
- a) the nucleotide sequence set forth in SEQ ID NO:2;
- b) a nucleotide sequence encoding the amino acid sequence set forth in SEQ ID NO:1;
- c) a nucleotide sequence having at least 75% sequence identity with the nucleotide sequence set forth in SEQ ID NO:2 wherein said nucleotide sequence having at least 75% sequence identity with the nucleotide sequence set forth in SEQ ID NO:2 encodes a polypeptide having adenylate cyclase activity;
- d) a nucleotide sequence having at least 85% sequence identity with the nucleotide sequence set forth in SEQ ID NO:2 wherein said nucleotide sequence having at least 85% sequence identity with the nucleotide sequence set forth in SEQ ID NO:2 encodes a polypeptide having adenylate cyclase activity;
- and
- e) a nucleotide sequence having at least 95% sequence identity with the nucleotide sequence set forth in SEQ ID NO:2 wherein said nucleotide sequence having at least 95% sequence identity with the nucleotide sequence set forth in SEQ ID NO:2 encodes a polypeptide having adenylate cyclase activity;
- said method comprising contacting the test compound with the nucleic acid molecule or a cell comprising the nucleic acid molecule under conditions suitable for the test compound to bind to the nucleic acid molecule and then determining whether the test compound forms a complex with the nucleic acid molecule.
A method for screening test compounds to identify a compound that modulates the level of a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:
- a) the nucleotide sequence set forth in SEQ ID NO:2;
- b) a nucleotide sequence encoding the amino acid sequence set forth in SEQ ID NO:
- 1;
- c) a nucleotide sequence having at least 75% sequence identity with the nucleotide sequence set forth in SEQ ID NO:2 wherein said nucleotide sequence having at least 75% sequence identity with the nucleotide sequence set forth in SEQ ID NO:2 encodes a polypeptide having adenylate cyclase activity;
- d) a nucleotide sequence having at least 85% sequence identity with the nucleotide sequence set forth in SEQ ID NO:2 wherein said nucleotide sequence having at least 85% sequence identity with the nucleotide sequence set forth in SEQ ID NO:2 encodes a polypeptide having adenylate cyclase activity;
- and
- e) a nucleotide sequence having at least 95% sequence identity with the nucleotide sequence set forth in SEQ ID NO:2 wherein said nucleotide sequence having at least 95% sequence identity with the nucleotide sequence set forth in SEQ ID NO:2 encodes a polypeptide having adenylate cyclase activity;
- in a cell, said method comprising contacting the test compound with a cell containing the nucleic acid molecule under conditions suitable for the test compound to modulate the level of the nucleic acid molecule and then determining the level of the nucleic acid molecule.
Dependencies are inferred from the claim text.